Inclusion Criteria:

• Age ≥ 18 years old.
• Refractory or relapsed non-Hodgkin lymphoma, as evidenced by 2 or more lines of prior  therapy.  
• Eastern Cooperative Oncology Group performance status 0 or 1.  
• Adequate renal, liver, cardiac and pulmonary organ function  
• Female subjects of childbearing potential and male subjects must agree to use  acceptable method(s) of contraception from enrollment through at least 12 months after CTX110 infusion.
• Agree to participate in an additional long-term follow-up study after completion of  this study.  

Exclusion Criteria:  

• Treatment with any gene therapy or genetically modified cell therapy, including CAR T cells.
• Prior allogeneic HSCT.  
• History of central nervous system (CNS) involvement by malignancy.
• History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia,  cerebellar disease, or any autoimmune disease with CNS involvement.  
• Presence of bacterial, viral, or fungal infection that is uncontrolled or requires IV  anti-infectives.
• Active HIV, hepatitis B virus or hepatitis C virus infection.  
• Previous or concurrent malignancy, except basal cell or squamous cell skin carcinoma,  adequately resected and in situ carcinoma of cervix, or a previous malignancy that was completely resected and has been in remission for ≥ 5 years.
• Use of systemic anti-tumor therapy or investigational agent within 14 days or 5 half-lives, whichever is longer, of enrollment.  
• Primary immunodeficiency disorder or active autoimmune disease requiring steroids  and/or other immunosuppressive therapy.   
• Women who are pregnant or breastfeeding.